Abstract:HepatoBiliary Surg Nutr 2021 | https://dx.doi.org/10.21037/hbsn-21-365 Colorectal liver metastases (CRLM) are one of the most frequent clinical conditions. Over the last 20 years, the clinical outcome for patients with CRLM has improved greatly. Liver resection is the gold standard treatment for resectable CRLM, achieving a 5-year overall survival (OS) rate of 42% (1). However, the majority of patients with CRLM are not candidates for resection. With the development of thermal ablation, this technique provides an alternative treatment modality by either ablation alone or combined with resection. A recent review by Takahashi et al. summarized the current role of thermal ablation in the management of CRLM (2). In this review, the authors stated that ablation should not be used in lieu of liver resection for resectable CRLM based on current available evidence. Regarding the rapid advancement of systemic and local therapy, the treatment strategies for patients with CRLM are suggested to be discussed by the multidisciplinary team (MDT). Also, the authors listed the indications of ablation in their center, including unresectable liver lesions (tumor number ≤8, tumor size ≤4 cm), combined with hepatectomy, and resectable liver lesions but patients unfit to receive resection because of comorbidities and patient preference. These indications are highly feasible and can be referred by readers. It is noteworthy that the preferred tumor size and number were inconsistent in the light of the clinician’s experience. In general, thermal ablation is recommended for tumor size ≤3 cm. For tumor size between 3 and 5 cm, welllocated tumors can also be effectively treated depending on anatomical position and the treatment protocol used (3). Tumor number varies from 5 to 9 in the literature, which depends on the total liver tumor volume. The authors then pointed out the pros and cons of 3 approaches to perform ablation. Open and laparoscopy approaches allow better staging for occult liver metastases or peritoneal disease and protect surrounding organs from thermal injuries. It has been reported that additional metastases were detected in 10–25% of patients with CRLM by intraoperative ultrasound (4), which may result in changing the surgical strategy. The percutaneous approach provides the least invasive approach and has a significant role in patients with limited recurrent liver metastases after resection or ablation. Moreover, percutaneous ablation can be used as the ‘test-of-time’ approach reported by Livraghi et al. (5). The rationale of this approach is: (I) high technical success rate of ablation for small tumors without the need for resection; (II) if ablation was unsuccessful, the resection was still feasible; (III) if patients develop additional lesions after ablation and would no longer be suitable for resection, they can be spared unnecessary surgery. Among the 88 patients treated in the study by Livraghi et al. (5), 26% remained free of disease without the need for resection, 24% underwent resection after ablation, and 50% were unfit for resection due to disease progression. Compared with liver resection, local tumor recurrence (LTR) is a major issue after ablation. Predictors of LTR include tumor size ≥3 cm and ablation margin ≤0.5 cm. In Editorial

Preliminary Results of Ultrasound-Guided Laser Ablation for Unresectable Metastases to Retroperitoneal and Hepatic Portal Lymph Nodes.

Percutaneous Laser Ablation: a New Contribution to Unresectable High-Risk Metastatic Retroperitoneal Lesions?

Percutaneous Laser Ablation of Unresectable Metastatic Lesions in Retroperitoneal Regions: A Series of 4 Cases

US-guided Percutaneous Laser Ablation of Refractory Metastatic Retroperitoneal Lesions

Comparison of Percutaneous Radiofrequency Ablation for Subcapsular and Non-Subcapsular Colorectal Cancer Liver Metastases

Clinical Outcomes and Predictors in Patients with Unresectable Colorectal Cancer Liver Metastases Following Salvage Percutaneous Radiofrequency Ablation: A Single Center Preliminary Experience

Ultrasound-guided radiofrequency ablation for the treatment of hepatic metastases:analysis of 136 cases

Percutaneous Thermal Ablation for the Treatment of Colorectal Liver Metastases and Hepatocellular Carcinoma: a Comparison of Local Therapeutic Efficacy

Percutaneous Laser Ablation of Hepatic Tumors Located in the Portacaval Space: Preliminary Results

Complex Liver Tumor: Does It Work when Endoscopic Ultrasonography and ND: Yag Laser Ablation Join Hands?

Percutaneous image-guided ablation for hepatic metastases

Laparoscopic Ultrasound Graded Radiofrequency Ablation for Hepatocellular Carcinoma:Preliminary Experience

The Current Application of Thermal Ablation in Colorectal Liver Metastasis.

MR-guided laser thermal ablation of primary and secondary liver tumours

Treatment Response and Preliminary Efficacy of Hepatic Tumour Laser Ablation under the Guidance of Percutaneous and Endoscopic Ultrasonography.

Radiofrequency Ablation Combined with Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma.

Treatment Strategy to Optimize Radiofrequency Ablation for Liver Malignancies.

Comparison of percutaneous ablation and hepatectomy for liver metastasis: A single center retrospective study

Radiofrequency Ablation Combined with Transarterial Chemoembolization for Treating of Hepatic Metastases

Clinical short-term results of radiofrequency ablation in liver cancers.

Role of Sonazoid enhanced ultrasound assistant laparoscopic radiofrequency ablation in treating liver malignancy—A single‐center retrospective cohort study